Institutional shares held 10.8 Million
5.9K calls
1.4K puts
Total value of holdings $17M
$9K calls
$2K puts
Market Cap $71.9M
45,510,800 Shares Out.
Institutional ownership 23.68%
# of Institutions 30


Latest Institutional Activity in CLLS

Top Purchases

Q3 2024
First Affirmative Financial Network Shares Held: 21.1K ($33.3K)
Q3 2024
Susquehanna International Group, LLP Shares Held: 13K ($20.6K)
Q3 2024
Morgan Stanley Shares Held: 91.5K ($145K)
Q3 2024
Citadel Advisors LLC Shares Held: 27.6K ($43.6K)
Q3 2024
Lpl Financial LLC Shares Held: 92.4K ($146K)

Top Sells

Q3 2024
Principal Financial Group Inc Shares Held: 412K ($651K)
Q3 2024
Baillie Gifford & CO Shares Held: 694K ($1.1M)
Q3 2024
Two Sigma Investments, LP Shares Held: 33.4K ($52.8K)
Q3 2024
Xtx Topco LTD Shares Held: 13.1K ($20.7K)
Q3 2024
Wells Fargo & Company Shares Held: 12.1K ($19.1K)

About CLLS

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.


Insider Transactions at CLLS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on CLLS

Follow Cellectis S.A. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CLLS shares.

Notify only if
Any

Insider Trading

Get notified when an Cellectis S.A. insider buys or sells CLLS shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to Cellectis S.A.

Track Activities on CLLS